Arvinas Hosts Fourth Annual Impact Day for Community Service
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: Newsfilter
- Employee Volunteerism: Arvinas employees across Connecticut and Greater Boston participated in the fourth annual Impact Day, engaging in volunteer activities that positively impact the community and reflect the company's commitment to patients and local areas.
- Diverse Community Projects: This year's activities included preparing meals for families with children needing medical care, creating blankets, and beautifying indoor and outdoor spaces, aimed at enhancing community quality of life and support capabilities.
- Partner Organization Support: Collaborating with organizations like Ronald McDonald House Charities, volunteers cleaned and organized spaces that support families, helping them feel warmth and care during medical challenges.
- Cultural Reflection: CEO Randy Teel emphasized that the passion and dedication of employees showcase the strength of Arvinas' culture and shared purpose, aiming to create lasting impacts for patients and communities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARVN
Wall Street analysts forecast ARVN stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.840
Low
15.00
Averages
16.00
High
18.00
Current: 8.840
Low
15.00
Averages
16.00
High
18.00
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arvinas Hosts Fourth Annual Impact Day for Community Service
- Employee Volunteerism: Arvinas employees across Connecticut and Greater Boston participated in the fourth annual Impact Day, engaging in volunteer activities that positively impact the community and reflect the company's commitment to patients and local areas.
- Diverse Community Projects: This year's activities included preparing meals for families with children needing medical care, creating blankets, and beautifying indoor and outdoor spaces, aimed at enhancing community quality of life and support capabilities.
- Partner Organization Support: Collaborating with organizations like Ronald McDonald House Charities, volunteers cleaned and organized spaces that support families, helping them feel warmth and care during medical challenges.
- Cultural Reflection: CEO Randy Teel emphasized that the passion and dedication of employees showcase the strength of Arvinas' culture and shared purpose, aiming to create lasting impacts for patients and communities.
See More
Arvinas Q1 2026 Earnings Call Insights
- FDA Approval Milestone: Arvinas recently received FDA approval for VEPPANU, marking a significant advancement in the company's drug development efforts, while entering a global licensing agreement with Pfizer enhances its market competitiveness.
- Revenue Decline: Revenue for Q1 2026 totaled $15.6 million, a substantial drop from $188.8 million in the same period of 2025, reflecting challenges in market promotion and product sales.
- Stable Cash Flow: As of the end of Q1, Arvinas reported $614.9 million in cash and cash equivalents, a decrease from $685.4 million at the end of 2025, yet maintains guidance for cash runway into the second half of 2028.
- Clinical Trial Progress: Although the ARV-102 trial in the U.S. is on hold due to additional data requested by the FDA, the company anticipates starting the U.S. trial by the end of 2026, which will not affect its plans for trials in the EU.
See More
Rigel Partners with Arvinas and Pfizer for Breast Cancer Treatment
- FDA Approval: Vepdegestrant, branded as Veppanu, received FDA approval earlier this month, becoming the only FDA-approved oral PROTAC therapy, which is expected to drive Rigel's cancer treatment portfolio expansion and enhance market competitiveness.
- Financial Gains from Agreement: Rigel will receive $70 million upfront and an additional $15 million upon completion of transition activities, along with potential future milestone payments of up to $320 million, significantly improving the company's financial outlook and investor confidence.
- Positive Stock Reaction: Rigel's shares surged over 15% following the announcement of the agreement, reflecting investor optimism regarding the new drug's market potential and indicating the company's growth prospects in oncology.
- Clinical Data Support: Veppanu demonstrated a 43% reduction in disease progression risk in Phase 3 studies, with a median progression-free survival of five months compared to 2.1 months for the comparator drug Fulvestrant, highlighting its significant therapeutic advantage.
See More
Arvinas Reports Q1 Earnings Miss with Significant Revenue Decline
- Earnings Report Disappointment: Arvinas reported a Q1 GAAP EPS of -$0.90, missing expectations by $0.26, indicating significant challenges in profitability for the company.
- Revenue Plummets: The company’s revenue of $15.6 million represents a staggering 91.7% year-over-year decline, falling short of market expectations by $19.24 million, reflecting a sharp decrease in product sales and market demand.
- FDA Approval Impact: Despite the FDA approval of Arvinas' breast cancer therapy, it failed to drive significant sales growth, suggesting potential shortcomings in market acceptance and promotional strategies.
- Uncertain Future Outlook: Given the current poor financial performance, investor concerns regarding Arvinas' future growth potential are rising, which may negatively impact its stock price and market confidence.
See More
Major Companies Reporting Earnings Next Week
- Strong Earnings Season Start: So far, 63% of S&P 500 members have reported earnings, with 84% exceeding analyst expectations, indicating market resilience and improved corporate profitability, which could positively impact stock prices.
- Palantir Earnings Expectations: Palantir Technologies is set to report earnings after the market closes on Monday, with analysts expecting earnings to more than double year-over-year due to strong AI and defense demand, potentially driving its stock price higher.
- Pfizer Drug Approval: Pfizer is scheduled to report earnings on Tuesday, and although a double-digit decline in earnings is expected, the FDA's approval of the breast cancer drug Veppanu may provide new revenue growth opportunities, with analysts remaining optimistic.
- McDonald's Earnings Outlook: McDonald's will report earnings on Thursday, with analysts forecasting single-digit growth in earnings and revenue, and the recovery in U.S. traffic suggests business revival potential, despite ongoing cost pressures.
See More
Arvinas and Pfizer Launch VEPPANU for Breast Cancer
- FDA Approval: Arvinas and Pfizer announced that the FDA has approved VEPPANU for adult patients with estrogen receptor-positive (ER+)/HER2-negative, ESR1-mutated advanced or metastatic breast cancer, marking Arvinas' first approved medicine and a significant milestone.
- Clinical Trial Results: In the pivotal Phase 3 VERITAC-2 trial, VEPPANU demonstrated a 43% reduction in the risk of disease progression or death compared to fulvestrant, with a median progression-free survival of 5 months versus 2.1 months for fulvestrant, indicating a substantial efficacy improvement.
- Safety Data: Safety data revealed that most adverse events were low-grade, with common side effects including fatigue, musculoskeletal pain, and laboratory abnormalities, suggesting VEPPANU's acceptable profile for clinical use.
- Market Potential: Breast cancer remains the most common cancer among women globally, and VEPPANU offers a new oral treatment option for patients resistant to endocrine therapy due to ESR1 mutations, expected to enhance patient outcomes and strengthen Arvinas' pipeline across oncology and other therapeutic areas.
See More
Arvinas Hosts Fourth Annual Impact Day for Community Service
- Employee Volunteerism: Arvinas employees across Connecticut and Greater Boston participated in the fourth annual Impact Day, engaging in volunteer activities that positively impact the community and reflect the company's commitment to patients and local areas.
- Diverse Community Projects: This year's activities included preparing meals for families with children needing medical care, creating blankets, and beautifying indoor and outdoor spaces, aimed at enhancing community quality of life and support capabilities.
- Partner Organization Support: Collaborating with organizations like Ronald McDonald House Charities, volunteers cleaned and organized spaces that support families, helping them feel warmth and care during medical challenges.
- Cultural Reflection: CEO Randy Teel emphasized that the passion and dedication of employees showcase the strength of Arvinas' culture and shared purpose, aiming to create lasting impacts for patients and communities.
See More
Arvinas Q1 2026 Earnings Call Insights
- FDA Approval Milestone: Arvinas recently received FDA approval for VEPPANU, marking a significant advancement in the company's drug development efforts, while entering a global licensing agreement with Pfizer enhances its market competitiveness.
- Revenue Decline: Revenue for Q1 2026 totaled $15.6 million, a substantial drop from $188.8 million in the same period of 2025, reflecting challenges in market promotion and product sales.
- Stable Cash Flow: As of the end of Q1, Arvinas reported $614.9 million in cash and cash equivalents, a decrease from $685.4 million at the end of 2025, yet maintains guidance for cash runway into the second half of 2028.
- Clinical Trial Progress: Although the ARV-102 trial in the U.S. is on hold due to additional data requested by the FDA, the company anticipates starting the U.S. trial by the end of 2026, which will not affect its plans for trials in the EU.
See More
Rigel Partners with Arvinas and Pfizer for Breast Cancer Treatment
- FDA Approval: Vepdegestrant, branded as Veppanu, received FDA approval earlier this month, becoming the only FDA-approved oral PROTAC therapy, which is expected to drive Rigel's cancer treatment portfolio expansion and enhance market competitiveness.
- Financial Gains from Agreement: Rigel will receive $70 million upfront and an additional $15 million upon completion of transition activities, along with potential future milestone payments of up to $320 million, significantly improving the company's financial outlook and investor confidence.
- Positive Stock Reaction: Rigel's shares surged over 15% following the announcement of the agreement, reflecting investor optimism regarding the new drug's market potential and indicating the company's growth prospects in oncology.
- Clinical Data Support: Veppanu demonstrated a 43% reduction in disease progression risk in Phase 3 studies, with a median progression-free survival of five months compared to 2.1 months for the comparator drug Fulvestrant, highlighting its significant therapeutic advantage.
See More
Arvinas Reports Q1 Earnings Miss with Significant Revenue Decline
- Earnings Report Disappointment: Arvinas reported a Q1 GAAP EPS of -$0.90, missing expectations by $0.26, indicating significant challenges in profitability for the company.
- Revenue Plummets: The company’s revenue of $15.6 million represents a staggering 91.7% year-over-year decline, falling short of market expectations by $19.24 million, reflecting a sharp decrease in product sales and market demand.
- FDA Approval Impact: Despite the FDA approval of Arvinas' breast cancer therapy, it failed to drive significant sales growth, suggesting potential shortcomings in market acceptance and promotional strategies.
- Uncertain Future Outlook: Given the current poor financial performance, investor concerns regarding Arvinas' future growth potential are rising, which may negatively impact its stock price and market confidence.
See More
Major Companies Reporting Earnings Next Week
- Strong Earnings Season Start: So far, 63% of S&P 500 members have reported earnings, with 84% exceeding analyst expectations, indicating market resilience and improved corporate profitability, which could positively impact stock prices.
- Palantir Earnings Expectations: Palantir Technologies is set to report earnings after the market closes on Monday, with analysts expecting earnings to more than double year-over-year due to strong AI and defense demand, potentially driving its stock price higher.
- Pfizer Drug Approval: Pfizer is scheduled to report earnings on Tuesday, and although a double-digit decline in earnings is expected, the FDA's approval of the breast cancer drug Veppanu may provide new revenue growth opportunities, with analysts remaining optimistic.
- McDonald's Earnings Outlook: McDonald's will report earnings on Thursday, with analysts forecasting single-digit growth in earnings and revenue, and the recovery in U.S. traffic suggests business revival potential, despite ongoing cost pressures.
See More
Arvinas and Pfizer Launch VEPPANU for Breast Cancer
- FDA Approval: Arvinas and Pfizer announced that the FDA has approved VEPPANU for adult patients with estrogen receptor-positive (ER+)/HER2-negative, ESR1-mutated advanced or metastatic breast cancer, marking Arvinas' first approved medicine and a significant milestone.
- Clinical Trial Results: In the pivotal Phase 3 VERITAC-2 trial, VEPPANU demonstrated a 43% reduction in the risk of disease progression or death compared to fulvestrant, with a median progression-free survival of 5 months versus 2.1 months for fulvestrant, indicating a substantial efficacy improvement.
- Safety Data: Safety data revealed that most adverse events were low-grade, with common side effects including fatigue, musculoskeletal pain, and laboratory abnormalities, suggesting VEPPANU's acceptable profile for clinical use.
- Market Potential: Breast cancer remains the most common cancer among women globally, and VEPPANU offers a new oral treatment option for patients resistant to endocrine therapy due to ESR1 mutations, expected to enhance patient outcomes and strengthen Arvinas' pipeline across oncology and other therapeutic areas.
See More
